November 2014

Editors’ Welcome

• Brenda Banwell,
• Gavin Giovannoni,
• Chris Hawkes,
• Fred Lublin

Acknowledgement to Reviewers

Economic costs associated with an MS relapse

• K. O׳Connell,
• S.B. Kelly,
• E. Fogarty,
• ...
• M. Hutchinson,
• C. McGuigan,
• N. Tubridy

Treatment adherence and transitioning youth in pediatric multiple sclerosis

• Sabeen Lulu,
• Laura Julian,
• Emma Shapiro,
• Kyr Hudson,
• Emmanuelle Waubant

MS-like presentations of HTLV-1 infection: Case-series and review of literature

• A. Moghadam-Ahmadi,
• R. Boostani,
• Z. Tafakhori,
• A. Sharifi-Razavi

Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a Nation-Wide Cohort

• R. Alroughani,
• S. Akhtar,
• S. Ahmed,
• J. Al-Hashel

Demographics and clinical characteristics of pediatric onset multiple sclerosis

• R. Alroughani,
• S. Ahmed,
• J. Al-Hashel

Cognitive impairment in patients with clinically isolated syndrome

• N.B. Moghadam,
• M.E. Moayed,
• M.A. Sahraian,
• N. Ameli

Progression from radiologically isolated syndrome to multiple sclerosis

• M.M. Koushki

Association between trigeminal neuralgia and multiple sclerosis: A population-based study

• M.M. Koushki

A case of acute disseminated encephalomyelitis mimicking multiple sclerosis attack treated by plasmapheresis

• O. Anlar,
• O. Deniz

A prospective study on the prognosis of multiple sclerosis in Tunisia: Do we really have a distinct disease course in North Africa?

• Y. Sidhom,
• Y. Hizem,
• A. Nasri,
• ...
• M.B. Djebara,
• A. Gargouri,
• R. Gouider

Inflammatory cytokines in relapsing-remitting multiple sclerosis (RRMS) patients

• M. Shaharian,
• F. Alsahebfosoul,
• M. Etemadifar

Neuromyelitis optica: Case reports from Oman

• M.A. Musafir,
• S. Kumar,
• K. Shaikhly,
• A. Zayed,
• F. Walli

A large series of Toxocara canis myelitis

• R. Jabbour,
• R. Sawaya,
• B. Yamout,
• S. Kanj-Sharara,
• S. Atweh

Pediatric onset multiple sclerosis patients tend to have slower disease progression

• R. Alroughani,
• S. Ahmed,
• J. Al-Hashel

HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients

• R. Abolfazli,
• S. Samadzadeh,
• E. Tabibian,
• A. Shakoori,
• S.R. Dehgolan

Genetics of MS in Saudi Arabia

• M.A.A. Jumah

Epidemiology of multiple sclerosis in the Middle East: A systematic review and meta analysis

• Z. Nasr,
• M. Etemadifar,
• B. Khalili

Evaluation of SNP rs763361 on Gly307Ser gene in multiple sclerosis patients compared to healthy subjects

• F. Alsahebfosoul,
• R. Salehi,
• A.Z. Hosseini,
• M. Etemadifar,
• M. Kazemi,
• M.H. Tajodin

Role of microchimeric cells in pathogenesis of multiple sclerosis

• M. Farokhi,
• M. Etemadifar,
• A. Rezaei

Brain MRI findings in Iranian patients with optic neuritis

• Z. Tafakhori,
• A. Moghadam-Ahmadi,
• A. Sharifi-Razavi

Intracranial Germinoma: Very rare mimicker of multiple sclerosis

• J. Inshasi,
• A. Almadani,
• S. Alrukn,
• S. Abdool,
• A. Alboudi

Comparative investigation of different sequences of Magnetic Resonance Imaging such as FLAIR, T2WI and PDWI in detection of Multiple Sclerosis patients referred to Magnetic Resonance Imaging Department of Imam Khomeini Hospital, Urmia, Iran

• N. Mohammadzaie,
• S. Taghavifar,
• A. Mosarrezaii,
• A.H. Asl,
• E. Faryar

Role of histamine and diamine oxidase enzyme in Multiple Sclerosis

• M. Farokhi,
• M. Etemadifar,
• A. Rezaei,
• A. Amani,
• H. Jahanbani

Role of adiponectin in multiple sclerosis

• A.A. Beni,
• M. Etemadifar,
• A. Rezaei,
• M. Farokhi

Investigation of Oncostatin M protein expression in Iranian relapsing remitting multiple sclerosis patients

• P. Alikhani,
• F. Alsahebfosoul,
• M. Shajarian

Effects of recurrent fasting on fatigue and quality of life in patients with multiple sclerosis

• Z. Nasr,
• M. Etemadifar,
• F. Sayahi,
• N. Toghianifar,
• M. Akbari,
• M.F. Esfahani

A study of general health status and depression in multiple sclerosis patients and its relation with some of their individual characteristics in the Urmia City, Islamic Republic of Iran

• N. Mohammadzaie,
• S. Taghavifar,
• A. Mosarrezaii,
• N. Ghasemzadeh,
• A.Y. Azar

Real world use of fingolimod in patients with relapsing remitting multiple sclerosis: A retrospective study utilising the national multiple sclerosis registry in Kuwait

• J. Al-Hashel,
• S. Ahmed,
• R. Behbehani,
• R. Alroughani

Severe reactivation of multiple sclerosis after discontinuation of fingolimod: An IRIS-associated phenomenon

• R. Alroughani,
• R. Alroughani,
• A. Almulla,
• S. Lamdhade,
• A. Thussu

The risk of short-term relapse in patients switching from natalizumab to fingolimod

• R. Alroughani,
• S. Ahmed,
• J. Al-Hashel

Efficacy and safety of fingolimod treatment in multiple sclerosis: The clinical experience of the AUBMC Multiple Sclerosis Center in Lebanon

• B. Yamout,
• S. Khoury,
• M. Zeineddine,
• R. Hourany

Fingolimod (Gilenya) may improve the chances of conception in women with multiple sclerosis (MS) associated with secondary infertlity

• J. Inshasi,
• A. Almadani,
• S. Alrukn,
• A. Alboudi

Mesenchymal stem cell therapy in multiple sclerosis: An updated review of the current clinical trials

• O. Mirmosayyeb,
• R. Meamar,
• A.P. Tanhaie,
• N. Eskandari,
• V. Shaygannejad

Consistent reduction in the annualized rate of brain volume loss across phase 3 core and extension trials of fingolimod in relapsing multiple sclerosis

• E.W. Radue,
• T. Sprenger,
• P. Chin,
• D.P. Meier,
• N. Sfikas,
• F. Barkhof

PANGAEA: Post-authorization Noninterventional German Safety Study of GilEnyA in relapsing-remitting multiple sclerosis (RRMS) patients: A 24-month interim analysis of a German five-year fingolimod registry study

• T. Ziemssen,
• M. Diaz-Lorente,
• M. Abdelkader,
• C. Cornelissen

Four-year Expanded Disability Status Scale (EDSS) outcomes in patients treated with fingolimod in the Phase 3 and extension trial program

• Bruce Cree,
• P. Chin,
• S. Ritter,
• ...
• P.V. Rosenstiel,
• S. Casiano,
• L. Kappos

Long-term safety of fingolimod: Interim evaluation of data from the longterms trial

• P.V. Rosenstiel,
• R. Gottschalk,
• L. Cappiello,
• Y. Zhang,
• M. Said,
• L. Kappos

Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial

• L. Kappos,
• A. Bar-Or,
• B. Cree,
• ...
• E. Lam,
• H. Pohlmann,
• E. Wallström

Categorical change in T2 lesion volume and clinical outcomes in the Phase III FREEDOMS and its extension study, evaluating fingolimod in patients with relapsing-remitting multiple sclerosis

• D. Jeffery,
• E.V.D. Cantogno,
• D.P. Meier,
• M. Meinel,
• P. Chin,
• A. Shamim